Benzinga | Aug 2, 2021 08:16AM EDT

Hoth Therapeutics Reports Initiation Of Preclinical Study Of HT-ALZ For Alzheimer's Disease

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.



The goal of the study is to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and to determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease. Hoth study will also determine if behavior is improved utilizing HT-ALZ in blocking NK-1Rs. To evaluate other forms of memory, we will also determine if chronic HT-ALZ treatment influences non-spatial memory using a novel object recognition and novel object location task. These tests will give us the ability to assess both hippocampal and non-hippocampal dependent memory. Additionally, these tests do not require food or water deprivation to motivate the animals, which may interfere with drug delivery or dosing regulation over time.

The designed studies are taking place under a Scientific Research Agreement entered by Hoth as of June of this year.